• Japanese
  • Korean
  • Chinese
Cover Image

Human Vaccines

Abstract

Description

This report analyzes the worldwide markets for Prophylatic Human Vaccines in US$ Million by the following Product Segments: Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report also analyzes the world market for Therapeutic Vaccines for the period 2010 to 2015. The report profiles 162 companies including many key and niche players such as ALK - Abello A/S, Bavarian Nordic A/S, Crucell N.V., CSL Ltd., GlaxoSmithKline PLC, GlaxoSmithKline Biologicals S.A, Medimmune, Inc., Merck & Company, Inc., Novartis Vaccines & Diagnostics, Inc., Sanofi, Sanofi-Pasteur SA, Sanofi Pasteur, Inc., Shanta Biotechnics Ltd., Vaxin, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Prophylactic Vaccines
    • Therapeutic Vaccines

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW & OUTLOOK

  • Human Vaccines Market Remains Resilient to Recession
  • Global Human Vaccines Market: A Snapshot
  • Market Dynamics
  • Vaccine Pricing: The Developed - Developing Divide
  • Growth Drivers in a Capsule
  • Developed World: The Key Markets
  • Looking Ahead
  • Emerging Markets: The Future Growth Area
  • Competitive Scenario
  • World's Leading Producers
    • Table 1: Leading Players in the Worldwide Vaccines Market (2008): Market Share Breakdown by Value Sales for GlaxoSmithKline, Sanofi-Aventis, Merck & Co., Novartis, Wyeth, and Others (includes corresponding Graph/Chart)
  • ALK- The Global Leader in Allergy Vaccines
    • Table 2: Leading Players in the Worldwide Allergy Vaccines Market (2005 & 2006 - A Historic Perspective): Market Share Breakdown of Value Sales (*) for ALK- Abello, Stallergenes, Allergopharma, and Others (includes corresponding Graph/Chart)

2. PRODUCT OVERVIEW

  • Introduction to the Concept of Immunity
  • Role of Vaccines in Strengthening the Immune System
  • Vaccines and Immunotherapy
  • Historical Overview of Vaccines
  • How it Began
  • So Far So Good
    • Successful Vaccine Introductions in the Past
  • Contribution of Animal Research to Vaccine Production
  • Types of Vaccines
  • Live, Attenuated Vaccines
  • Combination Vaccines
  • Killed or Inactivated Vaccines
  • DNA & Recombinant DNA Vaccines
  • Toxoids
  • Cellular Fractions
  • Conjugate Vaccines
  • Subunit Vaccines
  • Passive Immunization
  • Prophylactic Vaccines
  • Prevention Better than Cure
  • Prophylactic Pediatric Vaccines
    • Vaccination Over the Years
  • A Mature Market
    • Challenges for Pediatric Vaccines Market
  • BCG Vaccine
    • Growth Boosting Factors for TB Vaccines
    • Demand Restraining Factors for TB Vaccines
    • Major Issues to be Addressed in the TB Vaccine Market
    • Table 3: Global Historic Review for TB Vaccines Market: Annual Sales for Years 2000 through 2005 (In US$ Million) (includes corresponding Graph/Chart)
  • Hemophilus Influenza Type B Vaccine
    • Hib and Combination Vaccines by Producer
    • Table 4: Historic Review for Pediatric Haemophilis Influenza B Vaccine Market in the US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
    • Table 5: Historic Review for Pediatric Haemophilis Influenza B Vaccine Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)
  • Diphtheria/Tetanus/Pertussis Vaccines
    • DTP, DTaP, and Combination Vaccines Offered by Major Producers in US
    • Table 6: Leading Players in the US DTP and DTaP Vaccines Market (2003-2005 - A Historic Review): Market Share Breakdown of Value Sales for Sanofi Pasteur, Wyeth, GlaxoSmithkline, and others (includes corresponding Graph/Chart)
    • Table 7: Historic Review of DTP and DTaP Vaccines Market in the US: Annual Sales for 2000- 2005 (In US$ Million) (includes corresponding Graph/Chart)
    • Table 8: Historic Review of DTP Vaccine Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
  • Hepatitis A Vaccine
  • Hepatitis B Vaccine
  • Hepatitis B Epidemiology
    • Table 9: World Market for Hepatitis B Vaccines: Annual Sales for Years 2009 through 2017 (In US $ Million) (includes corresponding Graph/Chart)
    • Table 10: Historic Review for Hepatitis B Vaccines Market in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
  • Measles/Mumps/Rubella Vaccines
    • Table 11: Historic Review for Measles-Mumps- Rubella (MMR) Vaccine Market in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
    • Table 12: Historic Review for Measles-Mumps-Rubella (MMR) Vaccine Market in the US: Annual Sales for 2000-2005 (In Millions of Doses) (includes corresponding Graph/Chart)
  • Rotavirus Vaccines
  • Polio Vaccines
    • Table 13: Historic Review for Polio Vaccines Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
    • Table 14: Historic Review for Polio Vaccines Market in the US: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
    • Table 15: Historic Review for Polio Vaccine Market for Both Vaccine Types in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)
    • Table 16: Historic Review for Polio Vaccine Market for Both Vaccine Types (OPV and IPV) in the US in Percent of Doses from 2000-2005
  • Varicella Vaccine
    • Table 17: Historic Review for Varicella Vaccine Market in the US and Europe: Annual Sales for 2000- 2005 (In US$ Million) (includes corresponding Graph/Chart)
    • Table 18: Historic Review for Varicella Vaccines Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)
  • Need for Combination Vaccines
  • Prophylactic Adult Vaccines
  • Favorable Market Growth
  • Hepatitis A Vaccine
  • Hepatitis B Vaccines
    • Key Issues Affecting the Adult Hepatitis Vaccines Market
  • Cholera Vaccine
  • Hepatitis A/Hepatitis B Vaccine
  • Japanese Encephalitis Vaccines
  • Influenza Vaccines
    • Table 19: Global Flu Vaccines Market by Region (2005): Percentage Share Breakdown of Value Sales for the US, EU, and Rest of the World (includes corresponding Graph/Chart)
    • Table 20: Global Flu Vaccines Market by Leading Players (2005): Market Share Breakdown by Volume Sales for Sanofi Pasteur, Chiron, GSK and Others (includes corresponding Graph/Chart)
    • Table 21: Rate of Influenza Vaccine Consumption Among Target Groups (includes corresponding Graph/Chart)
    • Table 22: Global Historic Review for Adult Influenza Vaccines: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
  • Growth Boosting Factors for Influenza Vaccines Market
  • Key Issues Affecting Influenza Vaccines Market
    • Age-Driven Strategies Drive Target Market for Influenza Vaccines
    • Healthcare Professionals Increase Target Market for Influenza Vaccines
  • Lyme Disease Vaccine
  • Pneumococcal Disease Vaccines
  • Meningococcal Vaccines
  • Rabies Vaccines
    • Table 23: Global Historic Review for Rabies Vaccines: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)
  • Typhoid Vaccine
  • Yellow Fever Vaccine
  • Need for Additional Vaccines
  • Therapeutic Vaccines
  • DNA Holds the Key
  • Huge Potential for Protein Based Vaccines
  • Therapeutic Hepatitis Vaccines
  • Therapeutic Addiction Vaccines
  • Cancer Vaccines
    • Human Papillomavirus (HPV) Vaccine
    • Breakthroughs in Cancer Vaccine Market
    • Factors Affecting the Market for Cancer Vaccines
  • Vaccine for AIDS
    • What is AIDS?
    • Global Statistics
    • Table 24: Worldwide HIV/AIDS - 2007 (includes corresponding Graph/Chart)
    • Table 25: Worldwide HIV & AIDS Incidences (2007): A Regional Breakdown for Living and Newly Infected Cases (includes corresponding Graph/Chart)
    • Table 26: Worldwide HIV & AIDS Prevalence Rate in Adults Aged between 15 and 49 Years for the Year 2007 (includes corresponding Graph/Chart)
      • Asia-Pacific
      • Central Asia & Eastern Europe
      • Commonwealth of Independent States (CIS)
      • Latin America (Including the Caribbean Islands)
      • Sub Saharan Africa
      • North Africa & the Middle East
      • Developed Regions and High-Income Countries
      • United States
    • Table 27: New HIV Infection Cases among Men in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart)
    • Table 28: New HIV Infection Cases in the US (2006): Percentage Breakdown by Racial/Ethnic Groups (includes corresponding Graph/Chart)
    • Table 29: New HIV Infection Cases among Women in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart)
    • Development of Treatment Options
    • Categories of Vaccines for AIDS
    • HIV Vaccines Under Development
    • HIV Vaccines (Prophylactic/Therapeutic) Under Development: As of 2010
  • Malaria Vaccine
    • Therapeutic Vaccines Against Infectious Diseases: The Challenges
  • Melanoma: Prospects for Treatment
    • Melanoma Vaccines under Development: As of 2010
  • Autoimmune Diseases
    • How Do Autoimmune Diseases Occur
    • Types of Autoimmune Diseases
    • Need for Developing Autoimmune Therapeutic Vaccines
  • Travel Vaccines: Opportunities
    • SARS - A Review
      • Vaccinations Recommended for Travel to High-Risk Areas
  • Mechanisms for Vaccine Delivery
  • Edible Vaccines
  • Oral Vaccines
  • Tablet Based Vaccines
  • Mucosal Delivery
  • Transdermal Patch Delivery

3. MARKET TRENDS & ISSUES

  • Newer Vaccines in Pipeline to Cheer Up Pharma Companies
  • Select Vaccines Currently in Phase III Clinical Trials
  • Threat of Pandemic Rejuvenates Vaccine Market
  • Influenza Vaccines On a Growing Spree
  • H1N1 Vaccines Hit the Market in August 2009
    • H1N1 Influenza Vaccines and Manufacturers
  • Influenza Market Faces Several Challenges
  • Economic Factors Hamper Optimal Vaccine Development and Delivery
  • Increasing Need for Vaccine Promotion in the Developing Regions
  • Changing Vaccine Needs
  • DNA Vaccines: Engineering Growth
  • AIDS Vaccine: Long Road Ahead
  • HIV Vaccines Research Clipped by Lack of Funds
  • Funding Drops In HIV Vaccine Research Amid Recession
  • Noninjectable Vaccines: Gain Without Pain
  • Need for a Human Vaccine for Leishmaniasis
  • Conjugate Vaccines: A Technological Innovation
  • Need For a New TB Vaccine
    • Table 30: Worldwide Prevalence of TB Cases (in '000s) by Region for the Year (2007) (includes corresponding Graph/Chart)
  • Companies Involved in TB Vaccine Research: As of 2010
  • Religious Concerns Over Immunizing Young Girls Against Human Papillomavirus
  • Changing Travel Patterns Increase Demand for Hepatitis B Vaccine
  • DTaP Vaccines Approved for Booster Vaccination
  • Advances in Biotechnology Spearheading Vaccines' Growth
  • BioWarfare: Threat Perception and Preparedness
  • Overview of Potential Bio-Terrorist Agents
  • Smallpox (Variola Major)
  • Anthrax (Bacillus Anthracis)
  • Plague (Yersinia Pestis)
  • Botulism (Clostridium Botulinum)
  • Tularemia (Francisella Tularensis)
  • Market Concerns
  • Safety Factor
  • Development Delays
  • Storage Problems
    • Perfluorocarbons as Alternative to Overcome Storage Problems
  • Costs
  • Standards for Vaccine Safety and Quality

4. DISTRIBUTION CHANNELS

5. TECHNOLOGICAL DEVELOPMENTS

  • Applying Gene Therapy to Develop Therapeutic Solutions
  • Research and Trials of AIDS Vaccines
  • Ongoing Clinical Testing for AIDS Vaccines: Status As of 2010
  • International AIDS Vaccine Initiative (IAVI)
  • Cancer
  • Cancer Type and Area Effected
  • Immunotherapies for Cancer
    • Cancer Treatment Drugs
  • Issues Effecting the Development of Commercially Viable Cancer Vaccines
  • Frequency of Vaccination
  • Growth Boosters in the Cancer Vaccines Market
    • Available Cancer Treatment Vaccines
    • Select Cancer Vaccines (Therapeutic and Prophylactic) in Clinical Trials: As of 2010
    • Other Cancer Treatment Vaccines
  • Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines

6. CLINICAL TRIALS IN THE VACCINES MARKET

  • Vaccinogen Selects Clinipace for Phase 3b Clinical Trial with OncoVAX
  • BioSante to Restart Prostate Cancer Vaccine Clinical Testing
  • University of Oxford to Commence Phase 2b Proof-of- Concept Clinical Trials with TB Vaccine in Infants
  • Emergent Begins Phase I/II Clinical Studies of AIG for Anthrax Treatment

7. RESEARCH BREAKTHROUGHS - A HISTORIC PERSPECTIVE BUILDER

  • Favrille Announces Phase III Registration Trial Results of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
  • Novartis Announces Phase III Results of Menveo® Vaccine
  • Emergent Commences Phase II Clinical Study of Typhoid Vaccine
  • AVANT's Single-Dose Oral Ty800 Vaccine Meets Key Endpoints
  • Emergent BioSolutions' Typhoid Vaccine Completes Final Phase II Clinical Trial
  • Antigenics Announces Positive Data on Phase-I Study of ACAM-FLU-ATM Vaccine
  • Bavarian Nordic's IMVAMUNE® Post-Exposure Vaccination Demonstrates Protection Against Fatal Poxvirus Infection
  • BSU Scientists to Commence Human West Nile Vaccine Development Project
  • Intercell Concludes First Phase Clinical Studies of IC31® Adjuvanted Influenza Vaccine
  • Protherics Commences Phase 2 Angiotensin Vaccine Study
  • Novartis Receives European Approval for Optaflu® Flu Vaccine
  • CSL Biotherapies Files BLA for Influenza Vaccine
  • Orchestra Therapeutics Abandons Development of HIV Vaccine
  • AlphaVax Concludes Phase I Clinical Trial of Flu Vaccine
  • AVANT Presents Preclinical Data on Enteric Vaccine
  • Baxter Declares Results of Seasonal Flu Vaccine Candidate Trial
  • IDM Pharma Announces Interim Data of Phase II Clinical Trials of Lung Cancer Vaccine
  • Novavax Announces Developments in Discovery Program
  • Acambis Pioneers Testing of West Nile Virus Vaccine in Grown Ups
  • Acambis Initiates Test of single-dose JE vaccine in India
  • AVAX Technologies Initiates Phase 3 Clinical Trial For M-Vax
  • LigoCyte Pharmaceuticals Begins Clinical Testing of Norovirus Vaccine
  • Alphavax Initiates Clinical Testing for Flu and CMV Vaccines
  • Sanofi Pasteur Begins Phase 2 Testing of New Influenza Vaccine
  • Antigenics Reveals the Preliminary Data of Clinical Trial of Oncophage®
  • Baxter Reveals Phase I/II Clinical Trial Results of H5N1 Pandemic Vaccine
  • Crucell and AERAS Initiates Tuberculosis Vaccine Clinical Trial
  • DOR BioPharma Announces Phase I Results of RiVax™
  • GlaxoSmithKline Starts Clinical Trials to Test H5N1 Pandemic Flu Vaccines
  • MedImmune Initiates Phase I Clinical Trial of Avian H5N1 Vaccine
  • MedImmune Reveals Results of Phase 3 Study for CAIV-T
  • MedImmune Initiates Second Phase 1 Study with MEDI-534
  • Sanofi Pasteur Initiates First Clinical Trial of Cell Based H7N1 Vaccine
  • Therion Biologics Completes Enrollment for Phase III trials of PANVAC-VF
  • ViRexx Finishes the Treatment in Phase I Study of Hepa Vaxx B Vaccine
  • Antigenics Begins Phase I Clinical Trial of AG-707
  • Positive Results in Novavax's Pandemic Influenza Vaccine Pre-clinical Trials
  • Trials Reveal H5N1 Pre-Pandemic Vaccine of Sanofi Pasteur Effective
  • PowderMed Reveals Results for Phase 1 Trials for Influenza Vaccine
  • Phase II clinical trials of China's hepatitis B vaccine
  • Findings Prove New Nose-Spray Vaccines Effective
  • Large Doses of H5N1 Influenza Vaccine Appears Effective
  • New Vaccine Technology to Prevent TB
  • HPV Vaccine to Help Prevent Cervical Cancer
  • Scientists Develop H7N1 Avian Influenza Vaccine
  • Human H5N1 Vaccine Developed by Central Hygiene and Epidemiology Institute

8. PRODUCT DEVELOPMENT/LAUNCHES

  • Vivalis and SAFC Launch Ex-Cell EBx Media

9. PRODUCT DEVELOPMENT/LAUNCHES - A HISTORIC PERSPECTIVE BUILDER

  • MSD Pharmaceuticals India Launches GARDASIL Vaccine
  • Sanofi-Aventis Introduces ActHIB Vaccine in Japan
  • Sinovac Biotech Introduces Anflu®
  • Nventa Biopharmaceuticals Develops Poly IC-Poly Arginine
  • Replikins Develops New Synthesized Vaccine
  • GlaxoSmithKline Biologicals Launches Cervarix
  • CSL Develops New Vaccine for Prevention of Bird Flu
  • GlaxoSmithKline to Introduce Five Key Medicines for Oncology
  • FFF Enterprises Unveils My Flu Vaccine Network
  • Nabi Biopharmaceuticals to Develop NicVax Vaccine for Reducing Nicotine Effects
  • GenPhar Develops Highly Effective Tetravalent Dengue Vaccine
  • Iomai Commences the Development of Prophylactic Traveler™s Diarrhea Vaccine
  • Biological Immunological to Produce and Sell r-Hepatitis B Vaccine
  • Thailand Researchers Commence the Development of Human Bird Flu Vaccine
  • USV to Commercialize Typhoid Vaccine
  • ALK-Abello Introduces GRAZAX® Anti-Allergy Vaccine
  • Novartis Unveils Influenza Virus Vaccine Fluvirin®
  • Wyeth Introduces Latest 7-in-1 Pneumococcal Conjugate Vaccine
  • Intervet Releases Arnhem, a Prototype of Avian Influenza Vaccine
  • Shantha Launches 'Jencevac' Brain Fever Vaccine
  • Wockhardt and Zhejiang Introduces New Hepatitis- A Vaccine
  • GSK Introduces Rotarix(R) Vaccines for Infants
  • Sinovac Biotech Introduces Bilive™

10. RECENT INDUSTRY ACTIVITY

  • 'Sanofi-Aventis' Name Turns Simpler, Now Known as Just 'Sanofi'
  • Antigenics Changes Name to Agenus, Provides Pipeline Details
  • AltraVax Acquires Vaccine Development Technology Package from Maxygen
  • Pfizer Integrates R&D operations of Wyeth
  • Dendreon Receives FDA Approval for PROVENGE® Vaccine to Treat Men with Advanced Prostate Cancer
  • SVA and Parenteral Biotech Enter into a Partnership to Distribute and Supply Vaccines
  • Novartis Obtains FDA Approval for MenveoA® Vaccine
  • Pfizer to Supply Vaccine for Pneumococcal Disease
  • Torii Enters into Partnership with Riken
  • Sanofi-Aventis Acquires Shantha Biotechnics
  • Affitech AS Merges with Pharmexa A/S
  • Takeda Acquires IDM Pharma
  • Pfizer Concludes Wyeth's Acquisition
  • Sanofi Pasteur and Syntiron Sign Agreement to Develop and Market Prophylactic Vaccine
  • Cell Genesys Merges with BioSante Pharmaceuticals
  • Simcere Pharmaceutical Acquires Controlling Stake in ChinaVax
  • Novartis to Acquire 85% Stake in Zhejiang Tianyuan
  • FDA Approves Merck's Gardasil for Males under 9 to 26 Years Age
  • Merck Sign Agreement with CSL Biotherapies
  • Sinovac Forms JV with Dalian to Develop and Market Human-Use Vaccines
  • CPL Enters Into JV with Novavax
  • Nobilon Ties-up with WHO
  • GeoVax Labs to Relocate Operations
  • SingVax and Inviragen Merge
  • Sanofi-aventis and Mexican Authorities Enter into Agreement
  • Kitasato Institute and Daiichi Sankyo Ink Agreement
  • ACVD to Enter into Alliance with Emory Vaccine Center
  • Emory University to Set Up Emory Institute for Drug Discovery
  • ImmunoVaccine Technologies Enters into Partnership with FIT Biotech
  • VGX Pharmaceuticals Merges with Inovio Biomedical
  • Sanofi Pasteur Obtains EC Approval for INTANZA®/IDflu®
  • European Commission Grants Marketing Authorization to Ixiaro® Vaccine
  • US FDA Approves Ixiaro® Vaccine
  • Emergent BioSolutions Purchases Protein Sciences
  • Vaccine Technologies Signs Agreement with Celldex Therapeutics
  • Oxford-Emergent Tuberculosis Consortium and ProBio Gen Ink Agreement
  • JN-International to Acquire Biocor's Vaccine Research and Manufacturing Plant
  • Mymetics to Acquire Bestewil Holding BV
  • Eureka Genomics and Nanobac Pharmaceuticals to Merge
  • Immunovaccine Enters into Agreement with National Cancer Institute
  • GSK Forms Joint Venture with Walvax

11. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER

  • AVANT Adopts New Identity as Celldex Therapeutics
  • Eli Lilly Takes Over ImClone Systems
  • Sanofi Pasteur Acquires Acambis
  • Novartis to Acquire Protez
  • Novartis Inks Agreement with AlphaVax
  • Vacsera Signs Agreement with Omninvest
  • GeoVax Sign LOI with Vivalis
  • GlaxoSmithKline Receives EC Approval for Prepandrix Vaccine
  • ShigaMedix SAS and Avesthagen Sign Agreement
  • Shenzhen Neptunus Inks Agreement with Glaxo SmithKline
  • Sanofi Pasteur Establishes Vaccine Manufacturing Facility
  • Emergent BioSolutions Forges Joint Venture with the University of Oxford
  • Crucell Bags Contract from NIAID and NIH
  • PharmAthene Takes Over Business of Avecia
  • Crucell and Wyeth Pharmaceuticals Sign Agreement
  • Cytos Biotechnology and Pfizer Vaccines Sign Agreement
  • Intercell Acquires Iomai
  • Emergent BioSolutions to Acquire Recombinant Flu Vaccine, FluBlok®
  • Encorium Group Signs Contract with Protherics
  • Beijing Keyuan Xinhai Pharmaceutical Signs Agreement with China Biopharma
  • Callisto Merges with Celldex
  • Mymetics Corp. Buys Preventive Malaria Vaccine of Pevion Biotech AG
  • Dynavax Inks Agreement with Novartis
  • NasVax to Buy Protea Vaccine Technologies
  • Paladin Labs Buys ViRexx Medical Corp
  • Emergent BioSolutions Acquires Group of Anthrax Monoclonal Antibodies from AVANIR
  • China Biopharma and BKXPC Enter into Agreement
  • Encorium Signs Contract with Protherics for Phase 2 Trial of ATV for Hypertension
  • GenPhar to Establish Vaccine Production Plant in South Carolina
  • Intercell Partners SSI and Sanofi Pasteur to Further Develop TB Vaccine
  • Intercell and PATH Malaria Vaccine Initiative Form New Partnership for Malaria Vaccine
  • Intercell Receives Manufacturer's License for Production of JE Vaccine
  • GSK Receives US FDA Approval for ROTARIX® Rotavirus Vaccine
  • Dynavax and Merck & Co Announce Clinical Hold of HEPLISAV Vaccine Trial
  • Pharmexa and Ichor Enter into Co-Development Agreement for Multiple DNA Vaccines
  • Crucell Enters into Exclusive Development Agreement with Wyeth Pharmaceuticals
  • Crucell and Sanofi Ink an Agreement for Advanced Anti-Rabies Biologicals
  • FDA Confers Priority Designation for Supplemental Application for GARDASIL ®
  • Sanofi Submits a European Marketing Approval Application for First Influenza Vaccine
  • Lonza Consolidates Micobial Biopharma Operations
  • Novartis Acquires Rights Over a Novel Therapeutic Vaccine Candidate
  • AstraZeneca Purchases MedImmune
  • Nobilon Purchases EBx™ Cell Lines Rights from Vivalis
  • NasVax Inks Partnership Agreement with SciGen
  • GSK Inks Co-Promotion Agreement with Sinovac Biotech for Anflu
  • Pfizer Buys Coley Pharmaceutical Group
  • FDA Selects sanofi's H5N1 Vaccine
  • Novartis Starts Construction of a Cell-Culture Based Vaccine Production Facility
  • IVT Signs an MoU to Take Over Immunotope
  • Oxford BioMedica Takes Over Oxxon Therapeutics
  • DND Issues RFP for acquisition of MVA-based smallpox vaccine
  • GlaxoSmithKline Acquires Reliant Pharmaceuticals
  • GSK Acquires Praecis Pharmaceuticals
  • Berna Biotech Divests Stake in Pevion Biotech
  • GeoVax Signs a Private Placement Agreement with Pure Capital
  • Crucell Inks a Research License Agreement with ISU ABXIS of Korea
  • China Biopharma Concludes Capital Funding to ZT Biotech
  • Crucell and Acambis Ink a Licensing Agreement for PER. C6 ® Technology
  • Novartis and Intercell Join Hands to Advance Vaccine Programs
  • Serum Institute and Akorn Ink MoU for Vaccine Commercialization in US Market
  • Merck Plans to Establish a Human Vaccine Facility in Ireland
  • Schering-Plough Acquires Organon Bio Sciences
  • Intas Biopharmaceuticals Enters into Collaboration Agreement with Virionics
  • Oxxon Therapeutics Starts U.S. Operation
  • GenPhar and ImmuneRegen Enter into Research Partnership
  • Intercell Submits BLA for JE Vaccine to US FDA
  • AVANT and Select Vaccines Enter into R&D Partnership
  • AVAX Enters into Agreement with Cancer Treatment Centers of America
  • CSC's DVC and Baxter Receive Contract Modification from U.S. HHS
  • DOR BioPharma Enters into CRADA with Walter Reed Army Institute
  • Dynavax and Merck to Enter into Partnership to Develop Hepatitis B Vaccine
  • Emergent BioSolutions Commences Delivery of Bio Thrax® to US Health Department
  • Maxygen and Sanofi Pasteur sign License Agreement
  • Beijing Public Health Bureau Enters into Purchase Agreement with Sinovac
  • Novartis Wins US Government Contract for Developing Antigen Technology
  • MedImmune Announces Licensing of Reverse Genetics Technology to GlaxoSmithKline
  • MedImmune Wins US Government Contract
  • MedImmune and Human Genome Sciences Sign Lease Agreement
  • Acambis Announces Signing of Collaboration Agreement with Sanofi Pasteur
  • Acambis Announces JE Partnership Agreement with Sanofi Pasteur
  • Crucell Procures Major Patent for Influenza Vaccine Production
  • CSL Receives FDA Approval for Influenza Virus Vaccine
  • GlaxoSmithKline Inks Contract with UK Government
  • Merck & Co., Inc. and Dynavax to Jointly Develop Hepatitis B Vaccine
  • Sanofi Pasteur Wins Contract to Design, Retrofit and Maintain Influenza Vaccine Unit
  • Sanofi Pasteur Completes Construction of Influenza Vaccine Production Unit
  • Amgen Acquires Abgenix
  • Pfizer Acquires PowderMed
  • CancerVax and Micromet Merge to Establish Micromet, Inc.
  • Novartis Acquires Chiron
  • Dynavax Takes Over Rhein Biotech
  • AnGes and Vical Ink Collaborative Agreement
  • GeoVax Merges with Dauphin
  • Hawaii Biotech and Avantogen Merge to Form New Entity
  • CytoDyn Acquires Advanced Influenza Technologies
  • Emergent BioSolutions Acquires VIVACS
  • Acambis Divests Berna Business to Crucell
  • Novavax Inks an Agreement with Bharat Biotech to Develop Avian Flu Vaccine
  • Aeras Receives License for Developing and Distributing Tuberculosis Vaccine
  • Acambis to Supply Smallpox Vaccine to CDCP
  • AlphaVax and Wyeth Enhance Existing Licensing Agreement
  • Baxter Enters into a Contract to Supply Pandemic Influenza Vaccine
  • Sanofi Pasteur Signs Stockpile Contract with the US Government
  • Crucell Licenses PER.C6® Technology to ADImmune Corporation
  • Baxter Wins Stockpile Production Contract for H5N1 from the NHS
  • Crucell Earns NIH Contract to Develop HIV Vaccine
  • Novartis Secures Stockpile Supply Contract from the US Government
  • Novartis Signs Distribution Agreement with Intercell
  • GSK Receives Stockpile Supply Contract for Fly Pandemic from the HHS
  • GSK Signs H5N1 Antigen Influenza Vaccine Contract with Switzerland
  • DOR BioPharma Forms Alliance to Develop Ricin Vaccine
  • Nobilon and NVI to Jointly Develop RSV Vaccine
  • SciGen and OctoPlus Join Forces to Develop Hepatitis B Vaccine Delivery
  • AlphaVax Receives Patent for Alphavaccines Manufacturing Process
  • IVI Receives Funds for Cholera Vaccine Development Program
  • Novavax Forms Strategic Alliance with US-based, PacificGMP
  • Sanofi Pasteur Enters into Partnership with PDVI
  • MedImmune Inks a Cooperative R&D Agreement with NIAID
  • MedImmune Bags a Five-Year HHS Contract
  • Novavax Enters into a Cooperative Research Agreement with CDC
  • GlaxoSmithKline Establishes New Vaccine Manufacturing Facility
  • GenPhar Extends R&D Contract with NMRC
  • Medlmmune Files for INDA with FDA for a New Influenza Vaccine
  • Rotarix™ Vaccines Receives European Approval
  • Merck's GARDASIL® Receives FDA Approval
  • CDC Adds Merck's GARDASIL® Under its VFC Category in the US
  • Medlmmune Submits sBLA to the FDA Refrigerator-Stable Influenza Vaccine
  • Medlmmune Submits sBLA to the FDA for Expanded Label for CAIV-T
  • Medlmmune Receives FDA Approval for the Use of Reverse Genetics Technology
  • Vivalis Starts a New Plant in France to Produce Viral Vaccines
  • Fiocruz Provides Yellow-Fever Vaccine to Peruvian Government
  • Merck Receives FDA Approval for Zostavax Vaccine
  • The US Health and Human Services Department Awards Grant to Pharma Companies
  • GlaxoSmithKline Expands License and Supply Agreement with Antigenics
  • GlaxoSmithKline Applies for Approval for Cervical Cancer Vaccine
  • Omnia Biologics Signs Deal with Aeras Global TB Vaccine Foundation
  • Aeras Alliances with Dutch Scientific Organizations to Develop Latest TB Vaccines
  • Embrex, Shenzhen, and P.R. China Team Up for Manufacturing Influenza Vaccine
  • Health Canada Grants Approval to Merck's RotaTeq
  • HepaLife Technologies Receives License for Technology from MSU
  • Hindustan Latex Ties-up with Bharat Biotech for Marketing Vaccines
  • Emergent BioSolutions and Sanofi Pasteur Sign Agreement
  • USV and BCIL Enter into Agreement
  • GenVec Receives Fifth-Year Extension of Contract from NIAID
  • Inovio Joins Hands with Tripep to Develop Hepatitis C Vaccine
  • Novavax and Bharat Biotech Form Alliance to Develop Pandemic Flu Vaccine
  • Panacea Biotech Joins Hands with NVI to Create Polio Vaccine
  • Immune Response Ties Up with Accelsiors for Trial of NeuroVax Vaccine
  • Nordic Vaccine Joins Forces with Ace BioSciences to Develop Efficient Vaccines
  • Eisai Partners with DNAVEC to Develop New Vaccine
  • ViRexx Partners with DRDC to Develop Biodefence Vaccines
  • Biovirx Teams Up with IDT to Reintroduce Vaccine for Infants
  • LG Life Sciences Enters into Agreement with Sinovac
  • MediGene Awards Licenses to Virionics for CVLP Vaccine Program
  • FluLaval Influenza Vaccine Receives FDA Approval
  • Merck Applies for Approval to Market Gardasil in China
  • Bio-Bridge Establishes New Vaccine Facility in China
  • SIIL Established the First-ever Biotech SEZ in India
  • Aeras Foundation Establishes New Laboratory for TB Vaccine
  • China Biopharma Distributes Flu Vaccine in China
  • ViroPro Founds New Subsidiary for Developing Medicinal Vaccines

12. FOCUS ON SELECT GLOBAL PLAYERS

  • ALK - Abello A/S (Denmark)
  • Bavarian Nordic A/S (Denmark)
  • Crucell N.V. (The Netherlands)
  • CSL Ltd. (Australia)
  • GlaxoSmithKline PLC (UK)
  • GlaxoSmithKline Biologicals S.A (Belgium)
  • Medimmune, Inc. (USA)
  • Merck & Company, Inc. (USA)
  • Novartis Vaccines & Diagnostics, Inc. (USA)
  • Sanofi (Formerly Sanofi-Aventis SA) (France)
  • Sanofi Pasteur, SA (France)
  • Sanofi Pasteur Inc. (USA)
  • Shantha Biotechnics Ltd. (India)
  • Vaxin, Inc. (USA)
  • Wyeth (USA)

13. GLOBAL MARKET PERSPECTIVE

    • Table 31: World Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 32: World Historic Review for Human Vaccines (Prophylactic) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 33: World 15-Year Perspective for Human Vaccines (Prophylactic) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 34: World Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Segment - Pediatric and Adult Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 35: World Historic Review for Human Vaccines (Prophylactic) by Product Segment - Pediatric and Adult Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 36: World 15-Year Perspective for Human Vaccines (Prophylactic) by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric and Adult Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 37: World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 38: World Historic Review for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 39: World 15-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 40: World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 41: World Historic Review for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 42: World 15-Year Perspective for Adult Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 43: World Recent Past, Current & Future Analysis for Human Vaccines (Therapeutic) - Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
      • Growth Drivers
      • Market Constraints
      • Supply Shortages Mar Vaccines Market in Early Part of the Decade
    • Pediatric Vaccines Market
      • Market Focus Shifting From Pediatric Vaccines
      • Growth Drivers for US Pediatric Vaccines Market
      • Demand Restraining factors for US Pediatric Vaccines Market
    • Table 44: US Historic Review for Pediatric Vaccines: Annual Sales (In Millions of Doses) for Years 2000 through 2005 (includes corresponding Graph/Chart)
    • Table 45: US Pediatric Vaccines by Type in terms of Percent of Doses: 2000-2005 (includes corresponding Graph/Chart)
    • 'Bright' Outlook for Therapeutic Vaccines
      • Select Cancer Vaccines in Pipeline in the US: As of 2010
      • Market Share of Key Players in North America
    • Table 46: Leading Players in the North American Human Vaccines Market (2005 - A Recent Past Review): Market Share Breakdown of Value Sales for Merck, Sanofi-Aventis, Wyeth, Glaxo SmithKline and Others (includes corresponding Graph/Chart)
    • The US Influenza Vaccine Market
    • Table 47: The US Influenza Vaccine Market: Production and Distribution of Influenza Vaccine (In Millions) for the Period 2000-2001 to 2007- 2008 (includes corresponding Graph/Chart)
      • US DHHS Allocates US$1 Billion for Developing H1N1 Vaccine in 2009
      • 2007-2008 Influenza Vaccine Season
    • Table 48: Influenza Vaccine Producers for the Influenza Season (2007-2008): Market Share Breakdown in Production Terms for Sanofi Pasteur, Novartis, GlaxoSmithKline, MedImmune, and CSL (includes corresponding Graph/Chart)
    • 2005-2006 Influenza Vaccine Season
    • Table 49: Funds Forwarded by HHS for Influenza Vaccine Production (2005-2006) to Key Vaccine Manufacturers (In US Dollars) (includes corresponding Graph/Chart
      • Influenza Vaccine Producers for the 2006-2007 Influenza Season
      • Problems Effecting Timely Supply of Influenza Vaccine
    • Table 50: Influenza Vaccines Market in the US (2005 - A Historic Review): Percentage Breakdown of Value Sales for Sanofi Aventis, Chiron , GSK, and Medimmune (includes corresponding Graph/Chart)
    • Key Statistics
    • Table 51: Number of Children (In Millions) Under 5 Years of Age in the US: 2000-2005 (includes corresponding Graph/Chart)
      • Vaccines and Intended User Group
      • Need for Immunization Schedule for Adults
      • Adult Population: To Drive Future Growth of Pertussis Vaccines Market
    • Table 52: Pertussis Cases (In Millions) for Years 2000 through 2008 (includes corresponding Graph/Chart)
    • Federal Research & Grants
      • National Cancer Institute
      • National Institutes of Health (NIH)
      • NIH Scientists Showcase Potential West Nile Virus Vaccine
      • NIH Doles Out Grants to Biotech Companies
      • Development Funds for HIV Vaccines- Recent Past Data
      • Development Funds for Biodefense-Related Vaccines-Recent Past Data
      • The National Institute of Allergy and Infectious Diseases (NIAID)
      • Intramural Research
      • Extramural Divisions
    • Vaccine Pricing in the US
    • Table 53: Vaccine Prices (In US$ per Dose) in the US: 2002-2005 (includes corresponding Graph/Chart)
    • Regulatory Environment
      • Review Process Make Vaccines Safer
    • Imports-Exports Scenario: A Historic Perspective
      • Exports of Human Vaccines for 2004
    • Table 54: US Domestic Exports of Vaccines for Human Medicine for the Year 2004 (Value in '000 US Dollars) (includes corresponding Graph/Chart)
      • Imports of Human Vaccines for 2004
    • Table 55: US Imports of Vaccines for Human Medicine for the Year 2004 (Value in '000 US Dollars) (includes corresponding Graph/Chart)
    • Select Players
      • Alphavax, Inc.
      • Agenus Inc. (Formerly Antigenics, Inc.) (USA)
      • Antigenics, Inc.
      • Avax Technologies, Inc.
      • Baxter International, Inc.
      • Celldex Therapeutics, Inc.
      • Dendreon Corporation
      • Dynavax Technologies Corp.
      • Emergent BioSolutions Inc.
      • GenPhar, Inc.
      • Ligocyte Pharmaceuticals, Inc
      • Maxygen, Inc.
      • Micromet, Inc.
      • Novavax, Inc.
      • Progenics Pharmaceuticals, Inc.
      • Soligenix, Inc.
  • B. Market Analytics
    • Table 56: US Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 57: US Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment -Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 58: US 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • 2009 H1N1 Pandemic Boosts Vaccines Sales
      • H1N1 Vaccines Approved For Use in Canada
  • B. Market Analytics
    • Table 59: Canadian Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 60: Canadian Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 61: Canadian 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3. JAPAN

  • Market Analysis
    • Table 62: Japanese Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 63: Japanese Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 64: Japanese 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Overview
    • Table 65: Leading Players in the West European Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmith Kline, Wyeth, Novartis, and Others (includes corresponding Graph/Chart)
    • Vaccine Pricing in Europe
    • Major Drawbacks
    • Regulatory Mechanism for Vaccines in Europe
    • Sanofi Pasteur MSD (Europe) - A Leading Player
      • Market Share Statistics by Vaccines Category
    • Table 66: Leading Players in the European Pediatric Vaccines Market (2008): Market Share Breakdown of Value Sales for GlaxoSmithKline, Wyeth, Sanofi Pasteur MSD, and Others (includes corresponding Graph/Chart)
    • Table 67: Leading Players in the European HPV Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, and GlaxoSmithKline (includes corresponding Graph/Chart)
    • Table 68: Leading Players in the European for Flu, and Other Adult Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, Novartis, Solvay, and Others (includes corresponding Graph/Chart)
    • Table 69: Leading Players in the European Booster Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, Glaxo SmithKline, and Others (includes corresponding Graph/Chart)
    • Table 70: Leading Players in the European Travel Vaccines Market (2008): Market Share Breakdown of Value Sales for GlaxoSmithKline, Sanofi Pasteur MSD, and Others (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 71: European Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 72: European Historic Review for Human Vaccines (Prophylactic) by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 73: European 15-Year Perspective for Human Vaccines (Prophylactic) by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 74: European Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 75: European Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 76: European 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Table 77: Leading Players in the French Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, Wyeth, GlaxoSmithKline, and Others (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 78: French Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 79: French Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 80: French 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Table 81: Leading Players in the German Vaccines Market (2008): Market Share Breakdown of Value Sales for GlaxoSmithKline, Sanofi Pasteur MSD, Novartis, Wyeth, and Others (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 82: German Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 83: German Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 84: German 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Table 85: Leading Players in the Vaccines Market in Italy (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, Novartis, and Others (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 86: Italian Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 87: Italian Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 88: Italian 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Table 89: Leading Players in the Vaccines Market in the UK (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, and Others (includes corresponding Graph/Chart)
    • The UK Vaccine Industry Group (UVIG)
    • Select Players
      • BioVex
      • Oxford Biomedica PLC
  • B. Market Analytics
    • Table 90: UK Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 91: UK Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 92: UK 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Table 93: Leading Players in the Vaccines Market in Spain (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, and Others (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 94: Spanish Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years2009 through 2017 (includes corresponding Graph/Chart)
    • Table 95: Spanish Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 96: Spanish 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4f. RUSSIA

  • A. Market Analysis
    • Table 97: Leading Players in the Russian Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Novartis, and Others (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 98: Russian Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 99: Russian Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 100: Russian 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Table 101: Leading Players in the Vaccines Market in Rest of Europe (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, and Others (includes corresponding Graph/Chart)
    • Select Player
      • Intercell AG (Austria)
  • B. Market Analytics
    • Table 102: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 103: Rest of Europe Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 104: Rest of Europe 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/ Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Asian Vaccine Industry
    • Challenges
    • China
    • Table 105: Leading Players in the Vaccines Market in China (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur, GlaxoSmithKline, and Others (includes corresponding Graph/Chart)
    • Domestic Firms Occupy Major Share, Private/Foreign Companies Increase Market Share
      • Growth Drivers
    • Table 106: Central Government Funding for National Immunization Program (2004- 2008) (includes corresponding Graph/Chart)
      • State Drug Administration: Regulatory Authority in China
    • Imports of Vaccines
    • Coverage and Reimbursements
    • Research in Therapeutic Vaccines
    • India
    • Table 107: Leading Players in the Vaccines Market in India (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur (plus Shanta), Glaxo SmithKline, Serum Institute of India, Novartis, Panacea, Others (includes corresponding Graph/Chart)
      • Development Pipeline
    • Hepatitis B Vaccine in India
      • Panacea Biotec: A Leading Manufacturer of Hepatitis B Vaccine
    • Combination Vaccines
      • Indian Vaccine Market - Combination Vaccines Available in the Country
      • Indian Vaccine Market: New Combination Vaccines under Development by Major Companies As of 2010
    • International Players Entering the Arena
      • Major Partnerships Between Indian and International Players: A Recent Past Data
      • Heading Towards Greener Pastures
      • The Patent Act (Third Amendment), 2005
    • Select Players
      • GreenCross Vaccine Co., Ltd. (South Korea)
      • Human Biologicals Institute (India)
      • Panacea Biotec Limited (India)
      • Serum Institute of India, Ltd. (India)
      • Wockhardt Limited (India)
  • B. Market Analytics
    • Table 108: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 109: Asia-Pacific Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 110: Asia-Pacific 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • A. Market Analysis
    • Overview
    • Table 111: Leading Players in the Vaccines Market in Latin America (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur, Wyeth, GlaxoSmith Kline, Merck, Novartis, and Others (includes corresponding Graph/Chart)
    • Need for an effective TB Vaccine in Brazil
  • B. Market Analytics
    • Table 112: Latin American Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 113: Latin American Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 114: Latin American 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/ Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • Market Analysis
    • Table 115: Rest of World Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 116: Rest of World Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 117: Rest of World 15-Year Perspective for Human Vaccines (Prophylactic) by Product Group/ Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Show More
Pricing
Get Notified
Email me when related reports are published